Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Here's Why Novo Nordisk (NVO) is a Strong Momentum Stock
10:56am, Wednesday, 28'th Feb 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Novo Nordisk and Eli Lilly Stocks Slipped Today
06:01pm, Tuesday, 27'th Feb 2024
A rival's weight-loss drug candidate did well in a mid-stage clinical trial. The treatment met all of its endpoints in the study.
Stock Splits: Should You Buy?
04:26pm, Tuesday, 27'th Feb 2024
Many stock splits have occurred in recent years, with companies aiming to increase liquidity within shares and erase barriers to entry for potential investors. Lower share prices are more affordable f
Zealand's obesity drug shouldn't disrupt Novo Nordisk-Eli Lilly leadership: Mizuho's Jared Holz
06:32pm, Monday, 26'th Feb 2024
Jared Holz, Mizuho, joins 'Fast Money' to talk obesity drugmakers after a new study out of Zealand Pharma analyzed the impact of GLP-1s on liver disease.
Future Juggernauts: The Next 7 Trillion Dollar Companies to Buy Now
02:10pm, Monday, 26'th Feb 2024
Investors learned an important lesson in 2023: investing in the biggest companies and their stocks is a surefire way to capture strong gains. The Magnificent 7 – all of which are trillion dollar sto
These 2 carnivore dining stocks gaining on the Ozempic craze
11:53am, Monday, 26'th Feb 2024
The Ozempic and GLP-1 weight loss trend parallels the artificial intelligence (AI) mania that's gone mainstream viral, sending stocks like Novo Nordisk A/S NYSE: NVO and Nvidia Corp. NASDAQ: NV
Novo Nordisk and Eli Lilly rival soars 26% after promising weight-loss drug results
05:32am, Monday, 26'th Feb 2024
Zealand Pharma's Phase 2 trial was an "uniquivocal win" for a drug that can treat both liver disease and obesity, analysts said.
Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy
09:01pm, Thursday, 22'nd Feb 2024
Novo Nordisk had a near perfect FY23. Fundamentally, FY24 should look quite similar.
Why Novo Nordisk (NVO) is a Top Growth Stock for the Long-Term
10:51am, Wednesday, 21'st Feb 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
3 Top Sectors Investment Dollars Are Pouring Into Now: February 2024
03:45pm, Tuesday, 20'th Feb 2024
Top sectors are tough to pin down in advance. Far more often, we look backward at market performance to identify trends and top sectors.
Insider Buying: Taking a Controlling Stake in a Struggling Retailer?
11:20am, Sunday, 18'th Feb 2024
The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company's shares as he reportedly prepares to move to
Novo Nordisk Has More Than Ozempic. One of Its Other Treatments Grew 393% Last Year.
09:30am, Sunday, 18'th Feb 2024
While Ozempic is often affiliated with weight loss, the drug is not approved by the FDA for such a use. But its sibling treatment, Wegovy, is approved for chronic weight management in obesity patients
Novo Nordisk CEO says food execs are ‘scared' of weight loss drug threat
01:30pm, Thursday, 15'th Feb 2024
The feverish craze for Wegovy, Ozempic and other GLP-1 drugs is not over. It is prompting food executives to call the top boss at Novo Nordisk to ask for advice.
S&P 500's surge to new highs: Bull trap hiding in plain sight?
09:40am, Thursday, 15'th Feb 2024
The SPDR S&P 500 ETF Trust NYSEARCA: SPY is trading at new highs, but as the sharp pullback on February 13 showed, the rally may be showing signs of cracking.
Novo Nordisk: These Bold Moves Point Toward Upside
02:45am, Thursday, 15'th Feb 2024
Novo Nordisk's weight loss drug, Wegovy, shows potential for reducing cardiovascular risks by 20% in overweight or obese individuals. The company is actively working to scale up production of Wegovy t
